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Abstract 
This paper investigates the application of on-line near infra-red measurements as a means to 
measure blend uniformity in a continuous tableting line. Underlying all the monitoring and 
control methods is the ability to measure key tablet properties on-line at a rate suitable for 
control purposes. The use of NIR to determine any deviations in blend uniformity is 
demonstrated by interpreting the relevant spectral signature allowing quantitative information 
to be acquired for process monitoring and quality assurance. In addition to demonstrating the 
functionality of the NIR probe, the practical issues arising in the application are discussed.  
 
The composition of the blend was measured using an NIR probe over a range of concentrations 
and the results were calculated comparing sub unit dose scale of scrutiny of small populations. 
This was compared with predicted product quality for whole tablets over the whole production 
period. This technique has demonstrated how data collected online can be used to successfully 
predict the quality of the whole production run for the purposes of real time product quality 
assurance. 
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1. Introduction 
Over the last decade Process Analytical Technology (PAT) has become increasingly important in the 
pharmaceutical industry as it attempts to satisfy regulatory requirements and exploit advances in 
process design and technological capability. The aim of advanced process monitoring and control 
techniques when coupled with real-time data analysis is to drive processes towards more efficient, 
economic and robust operation. PAT can be used to monitor material characteristics or quality end-
point. This enables the generation of control loops for improvement of end-product quality based on 
the manipulation of input parameters, whether this is automated or through operator actions.  
 
Traditionally, batch process monitoring in the pharmaceutical industry has relied on taking samples 
during batch progression and at the end-of-batch for periodic off-line laboratory analysis. This 
approach is regarded as providing the necessary level of quality assurance for product release, but it 
also results in large material and operating redundancy. The technology to move to on-line 
measurement exists and is attractive, with the potential for much higher sampling frequencies, but its 
adoption has been slow. While the regulators have moved to accept PAT, to overcome the industry 
inertia to rapid on-line process analysis, PAT process monitoring techniques must demonstrate a 
suitable measurement accuracy and reliability that can produce quality assurance concomitant with 
industry requirements. A prime industrial driver is to demonstrate the capability and effectiveness of 
on-line techniques for assuring quality, with real time release (RTR) of the product being the sought 
after operating policy [1]. A balance arises between the introduction of novel and powerful 
measurement methods and the requirement to ensure consistent, repeatable with a (statistical) 
confidence in process outputs that are comparable to more traditional validated procedures.  
 
In a drive to increase operational efficiency and flexibility, the pharmaceutical industry is moving from 
batch to continuous processing [2]. However, the move to continuous processing causes online 
monitoring to become a necessity as product quality will vary with time. As with batch processing, 
continuous processing still requires the definition of a releasable entity in order to define a quantity of 
product which can be released or rejected based upon quality assurance criteria. With the development 
of instrumentation that is able to produce large quantities of high quality data quickly, the releasable 
entity size can be reduced. Reduction in this size allows for a significant reduction in risk of having to 
discard large quantities of out of specification material.  
 
With the addition of the time variable in continuous pharmaceutical processing, the need for a change 
in mind set away from end of batch quality assurance is needed. It is necessary for any process 
disturbances or drifts to be detected and suitable action taken before out of specification material is 
produced. Real time process control becomes more attractive during continuous production but 
requires both accurate and timely measurements to be made. PAT gives the ability for both of these 
allowing for a greater opportunity to implement real time process control in continuous pharmaceutical 
manufacturing. This view is echoed by Yu and Kopcha [3] who state from the FDA perspective 
‘continuous manufacturing and advanced PAT are necessary to broadly advance toward six sigma 
manufacturing quality’. 
 
2. Continuous Pharmaceutical Tablet Manufacturing 
 
Pharmaceutical manufacturing is historically performed batch-wise in discrete unit operations. Batch 
based primary pharmaceutical manufacturing has been the subject of intense research in terms of batch 
process control and automation [4]. Nevertheless, the lack of flexibility in batch processing in response 
to industry growth and a move within the industry to minimize the size of new manufacturing plants 
have given impetus for moving towards continuous processing in primary and secondary 
Manuscript <b>(must NOT contain author information)</b>
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manufacturing. From a broad business perspective there are hurdles to be overcome as discussed by 
Buchholz [5] when considering the overall whole process. 
 
Leuenberger [6] demonstrated the advantages of continuous manufacturing in a pharmaceutical 
granulation process. Leuenberger stated that the principal arguments for continuous operation are the 
ease of scale-up of unit operations and the theoretical possibility of uninterrupted, continuous 
manufacturing allowing for much greater operational efficiency and flexibility in the plant.  
 
Vervaet and Remon [7] presented a number of technologies for moving the granulation process from 
batch to continuous, including fluid-bed agglomeration, spray drying and extrusion. However, Plumb 
[8] presented the foremost argument for a change of mind-set in the pharmaceutical industry based on 
the FDA’s nascent recognition that continuous processing does have a place in modern pharmaceutical 
manufacture. This is reflected by changes in the regulatory and business environments. Plumb argued 
that, with the advent of PAT principles, there was a great opportunity for engineers to examine the 
possibilities for driving a step change in pharmaceutical manufacturing philosophy, whilst continuing 
to conform to GMP and GAMP. A review by Fonteyne et al [9], in addition to commenting on the 
limited number of applications of PAT to continuous pharmaceutical processes, observed that probe 
positioning can be problematic and probe fouling can be an issue. They further observed that the 
challenge of acting on the information from the probe for control purposes needs to be addressed. This 
is discussed further by Hattori and Otsuka [10] who consider the integrated control system / PAT 
challenge. 
 
2.1 On-line process measurement 
Control methods and approaches require the ability to measure process state, whether it is at the 
intermediate stages or the final product quality. Spectroscopy is a popular technology which fits into 
the FDA’s PAT framework. There are a number of different types of spectroscopy, Mid-Infrared 
(MIR), Near-Infrared (NIR) and Raman just to name a few. One of the major advantages with using 
one of these methods is that rapid online non-destructive measurements can be taken. Both MIR and 
NIR use the absorption of electromagnetic radiation to bring the molecules to a higher vibrational state. 
The molecular vibrations can occur in two ways, stretching and bending. Bending is defined as the 
change in bond angle and stretching is defined as the change in the inter-atomic distance along the 
plane of the bond [11]. In this application the greater path length associated with NIR offers distinct 
operational advantages. 
 
Spectroscopy is not a new technology with it traditionally being used in an offline analytical setting, 
though it has found many uses as an inline monitoring approach in many industries including batch 
fermentations. Menezes et al [12] describes several case studies that typify such application in 
upstream and product recovery. Considering formulation related applications, work by Roggo et al 
[13] and subsequently De Beer et al [11] reviews the applications of NIR for monitoring 
pharmaceutical production processes highlighting applications of NIR in blending, granulation, 
fluidised bed drying/granulators and freeze drying.  Others have also used NIR to characterise in-line 
blending performance [14-16]. 
 
The online determination of tablet quality has been considered by several authors. A number of quality 
measures are associated with tablets, one being dissolution rate. Pawar et al [17] applied NIR to 
determine the dissolution rate by relating principal components from the spectra to curve fit 
coefficients predicting the dissolution profile. While applied for a range of line operating parameters 
and API concentration variations, more general applicability remains to be demonstrated for different 
APIs and formulations. More typical of tablet quality assessment is the prediction of API concentration 
of the tablet. Fonteyne et al [9] provides a review of a number of applications of Process Analytical 
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Technology for API assessment in continuous pharmaceutical processing with focus on blending, 
spray drying, roller compaction, twin-screw granulation and compression. The review raises a number 
of common challenges experienced related to the ability to match calibration and operational 
conditions and implementation details that can cause significant long term operational difficulties 
related to sample presentation and fouling. They conclude by questioning the decision to utilise NIR 
as the method of first choice suggesting other techniques may be more suited.  Work by Jarvinen et al 
[18] and Vargas et al [19] demonstrated the ability of NIR to provide in-line concentration in a 
tableting line. Wahl et al [20] went further and considered not only the capability of the NIR 
measurement but also addressed concerns around blend uniformity (as discussed below). Casian et al 
[21] followed these approaches but also addressed the concerns of Fonteyne et al by comparing Raman 
and NIR based measurement approaches finding comparable performance on the specific examples 
they considered. Recent work by Li et al [22] demonstrated the capability of Raman spectroscopy and 
concluded that it is ‘a useful alternative to NIR’.  
 
Whether NIR or Raman spectroscopy is used, spectral processing is a necessity to remove any spectral 
baseline shifts due to changing sample presentation or any other external influence which may cause 
increased variation and therefore increased modelling errors. The main reasons for spectral processing 
are : 
 
 To process the data to keep the chemometric information while removing undesirable physical 
attribute effects.  
 To remove any outliers which are not representative of the process conditions. 
 
There are a number of well documented processing techniques which can be used to remove baseline 
shifts from the data. Some of the fairly common processing techniques are Standard Normal Variate 
(SNV), Multiplicative Scatter Correction, Baseline Correction and Savitzky-Golay Derivatives. Chen 
and Morris [23] highlight the different pre-processing techniques when a specific problem is 
encountered, such as temperature based spectral variation or variation because of the physical 
differences in samples. 
 
Physical factors also can have a significant effect on accuracy of NIR spectroscopy [24], including the 
changing particle size distribution of the powders/granules, with the SNV spectral treatment being 
especially effective.  
 
Calibration of the probe can be performed using a variety of methods, but predominately known 
calibration samples are manufactured and then used to calibrate the probe using a multivariate 
technique such as partial least squares. Though when using this method on the pharmaceutical 
production line, where the sample is in a granular form, the huge particle size distribution difference 
between the granular production samples and the powder based ideal lab samples will likely cause a 
large calibration error. Instead another method is used whereby the samples with which to build a 
calibration model are samples taken from the running production line. 
 
NIR instruments work by shining a spot of light onto the sample. When using an NIR instrument it is 
possible to estimate the mass of sample that is being measured. The sample mass can be estimated 
based upon the spot size, which is the circular projection of the area being measured, the penetration 
of the light into the granule and bulk density of the granule in question.  
 
When calculating the sample mass measured from an NIR instrument it is also important to understand 
the impact of measurement frequency. In general, when using an NIR instrument in the setup described 
in this paper, the measurement frequency will be much higher than the velocity of the powder flowing 
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past the probe itself. This will lead to large amount of re-sampling of the same material, and therefore 
a large volume of replicate data collection. 
 
2.2 Content Uniformity 
 
Content Uniformity is the measure of how much active ingredient is in a number of unit dose size 
samples. Content uniformity, unlike blend uniformity however is used on the final dosage form. There 
are also a number of regulatory requirements set out which must be met and which vary depending on 
the regulatory board which set them. For example, the US pharmacopeia states the following 
requirements must be met before releasing any product: 
 
 After testing 10 tablets, not more than one can be outside the range of 85% to 115% of the 
target concentration and there must be a relative standard deviation (RSD) of less than 6%. 
 If either of the above conditions are not met then a further 20 tablets must be tested, if only one 
is outside the 85% to 115% limits but within 75% to 125% of the target concentration and the 
relative standard deviation (RSD) of the total 30 tablets is within 7.8% then the requirements 
are met. 
 
However, it should be noted that different regulatory bodies have differing content uniformity 
requirements [25]. 
 
2.3 Blend uniformity 
 
Blend uniformity is the measure of homogeneity within a blend of different powders. Blend uniformity 
testing is recommended for dosage forms where content uniformity testing is also a requirement. 
 
Traditionally blend uniformity is a measure of the homogeneity of a batch blend. Representative 
samples are taken from different positions in the blend, and then spatial homogeneity can be proven. 
It is difficult to specify the number of samples required as this will be dependent on the specific process, 
but 6-10 different locations are recommended with three samples at each location. The samples should 
be equivalent to the unit dose which is produced in further manufacturing steps. The FDA recommends 
the following acceptance criteria for blend uniformity: 
 
 The mean assay is between 90% - 110% of target  
 The relative standard deviation is not more than 5% 
 
It can be noted that the blend uniformity requirements are more stringent than those specified by the 
content uniformity. This is to allow for any potential de-mixing which may occur in subsequent 
processing steps.  
 
Continuous manufacturing requires blend homogeneity both spatially and with time. Currently the 
regulatory bodies haven’t stated the blend uniformity requirements in continuous pharmaceutical 
manufacturing and therefore the above limits will be used in this study. 
 
2.4 Challenge Addressed 
Fundamental questions surrounding the scale of scrutiny arise in the application of PAT to assess tablet 
quality in continuous processing. Fundamentally from a patient perspective they are concerned about 
a single tablet concentration and the variation in concentration that could arise. Confidence to them 
relates to the mean and variation in API remaining within validated bounds. To move towards this 
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confidence, this paper firstly considers the offline predictive capability of the NIR probe when used to 
predict the active concentration levels compared to an offline standard measurement technique. In 
undertaking this comparison, it is necessary to address spectral data processing approaches. If 
predictive capability is proven, the next stage is to demonstrate the online performance of the NIR 
based prediction. Three aspects have been addressed. Firstly, blend uniformity is considered by 
looking at variation arising within individual dryer compartment cells through considering each sample 
of the NIR probe. Here high variation would be indicative of poor blend uniformity. Secondly, cell to 
cell variation is important to understand and mean and variance of NIR predictions per cell are 
compared to do so. Finally, the scale of scrutiny variation is considered from a single NIR measurement 
considering far less than a tablet dose to unit tablet dose. While intra-tablet variation maybe measured, 
it is the tablet dose scale of scrutiny that is indicative of patient delivery. In the cases addressed the use 
of a continuous tablet line subject to designed experiments is required and this is described in the first 
instance.  
 
3 Material and Methods 
 
3.1 Process Overview 
 
The equipment used in this research study was the GEA Consigma Continuous Tableting line [26]. 
This consists of a number of intensified processing steps taking the raw powders through to finished 
tablets. A flow diagram of the process is given in Figure 1.  
 
 
Figure 1 – GEA Consigma Continuous Tableting Line 
 
The process starts with a number of different powders that are fed using loss in weight screw feeders. 
Some of the powders may already be pre-blended using a tumble blender. For this work two screw 
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feeders were used, one feeder was used to dose the pre-blended placebo formulation, and the second 
to dose the saccharin that acted as an exemplar of an active pharmaceutical ingredient (API). However, 
powders have poor flow properties so the powder mixtures need to be granulated to the desired particle 
size distribution. The granulator is a twin screw granulator (TSG), which has an average residence 
time of 3 to 4 seconds.  
 
The wet granule is then transferred directly into the dryer that is a segmented fluidised bed dryer. Each 
segment acts as a small individual dryer, while every cell is subjected to the same inlet air. The act of 
using the segmented fluidised bed dryer splits the powder into smaller plugs which are given a tracking 
number as they pass through the rest of the system. These plugs are also referred to as cells.  
 
After drying, milling is undertaken to get a smooth size distribution of the particles and to remove any 
large particles which may have survived the drying process. The samples taken to determine the blend 
uniformity were from this position prior to the blender. The blender is a small batch blender, where 
lubrication is added via a lubrication dowser.  
 
The lubrication used is magnesium stearate and is necessary for successful tablet compaction. Finally, 
the tablets are pressed in the tablet press and this is the point that the composition of the tablets needs 
to be correct. The NIR instrument is placed above the press in the buffer hopper and is the two window 
version of the GEA diffuse reflectance lighthouse probe. 
 
 
3.2 Experimental protocol  
 
The experimental tests are designed to analyze the blend uniformity of the process using sodium 
saccharin as a marker. The sodium saccharin was dosed as a percentage of the GEA standard placebo. 
Importantly the sodium saccharin was dosed using a second screw feeder and is therefore independent 
of the flow rate of the rest of the formulation. The sodium saccharin was run at different concentrations, 
with the final aim of building a calibration model for the online NIR probe that could be used to 
measure the blend uniformity of a test dataset. Two experimental tests were developed in order to 
quantify the blend uniformity of the process under nominal conditions. The formulation was the GEA 
standard placebo with a varying percentage of sodium saccharin 100 mesh added.  
 
Table 1: Formulation  
Formulation Mass Fraction  (% w/w) 
Lactose 200M 72 
Corn Starch 24 
PVP 4 
Sodium Saccharin Varies 
 
The process was run under its nominal conditions except due to the sensitivity of sodium saccharin to 
water, the liquid addition rate (LAR) needed to be varied with the saccharin addition in order to 
maintain the granule quality. 
 
Table 2: Granulation Operating Parameters 
Run Mass Flow 
Rate 
Speed Liquid 
Addition 
Rate 
Jacket Temp 
# (kg/hr) (rpm) (%) (°C) 
1 25 700 varies 25 
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The tests undertaken were as follows: 
 
Table 3: Experimental Plan for Run 1 
Condition Placebo Mass Flow 
Rate 
Saccharin Mass 
Flow Rate 
Cell Number 
# kg/hr kg/hr # 
1 22.50 2.5 F1C1 - F2C5 
2 20 5 F3C1 – F4C5 
3 17.5 7.5 F5C1 – F6C5 
 
Table 4: Experimental Plan for Run 2 
Condition Placebo Mass Flow 
Rate 
Saccharin Mass 
Flow Rate 
Cell Number 
# kg/hr kg/hr # 
1 22.50 2.5 F1C1 - F2C5 
2 20 5 F3C1 – F4C5 
3 17.5 7.5 F5C1 – F6C5 
4 23.75 1.25 F8C1 – F9C5 
5 23.12 1.88 F10C1 – F11C6 
 
Here the cell number refers to compartmental drier cell and is a means of tracking product down the 
line. 
 
3.3 UV analysis 
UV analysis of the blend samples was carried out using a J&M Tidas II spectrometer with a scan range 
of 0-300 nm, an integration time of 300ms and 100 readings taken. The following method was used: 
 
 250mg of sample granule was weighed out and then dissolved in 250ml DI water, followed 
by filtration of non-soluble formulation components. This was repeated in triplicate 
 The blank was assessed using DI water in glass cuvette 
 The measurement was then taken using glass cuvette with given solution. If absorption was 
outside the 0-1AU range then further dilution was performed. Each measurement in the 
spectrometer was carried out in triplicate. 
 
3.4 NIR measurements 
The GEA lighthouse probe as stated before is a diffuse reflectance probe that contains a self-cleaning 
and calibration system. This means that it can remove the effects of fouling on the windows and using 
its calibration medium can regularly check that the windows have not become contaminated. Finally, 
the probe can be installed and used as an online as a monitoring tool and a diagram of this can be seen 
in Figure 2. 
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Figure 2 – The GEA lighthouse probe has three stages of operation. It takes a number of 
measurements, before retracting and gleaning itself, finally it uses its internal calibration medium to 
calibrate itself 
 
 
 
3.5 Data analysis and Model Building 
Data analysis was carried out using Matlab 7.10.0 (R2010a) and the Eigenvector Research PLS toolbox 
6.7.1.  
 
4. Results and discussion 
 
4.1 Data pre-processing 
With most process data it is typical to apply some simple pre-processing technique, such as scaling, 
prior to chemometric application. Particularly important is that spectral data generally have 
wavenumber regions that contain no information related to the properties of interest. These regions 
may be associated with noise artefacts related to the measurement device or areas unrelated to any 
physical or chemical property of interest. It is particularly important in chemometric analysis and 
model development to focus on the optimum wavenumber range and exclude those regions that contain 
no relevant information. 
 
Pre-processing requirements can be judged by observing the raw NIR spectrum. The raw spectra after 
non-valid readings were removed where the probe is not submersed in powder, were plotted and can 
be seen in Figure 3. Here the results for multiple time samples are shown. It is clear that such 
information is difficult to interpret in the raw form and a range of data pre-processing and information 
compression techniques are required. In order to pre-process the data, a Standard Normal Variate (SNV) 
transformation was applied to the raw spectrum and this can be seen in Figure 4. The SNV technique 
removes slope variation by individual wavelength samples. Here wavelength selection based on 
physical insight has been adopted but in more complex instances a variety of wavelength selection 
techniques are available [27, 28]. 
 
Figure 3: Raw NIR spectrum after non-valid reading removal for run 2 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
Figure 4 - NIR spectrum after Standard Normal Variate (SNV) Pre-processing for run 2 
 
4.1.1 Principal Component Analysis for Process Monitoring 
Using Principal Component Analysis it is possible to analyze whether the variation caused by changing 
the Sodium Saccharin concentration can be seen from the variation in the NIR absorbance spectrum. 
PCA was then applied to each run and the results can be seen from the loadings plot from principal 
component 2 in Figures 5 and 6.  
 
  
Figure 5: Principal Component 2 for Sodium Saccharin Run 1 at levels 10%, 20%, 30% 
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  Fi g ur e 6 : Pri n ci p al C o m p o n e nt 2 f or S o di u m S a c c h ari n R u n 2 at l e v els 1 0 %, 2 0 % a n d 3 0 %, 5 % a n d 
7. 5 %  
 
H er e it is pri n ci p al c o m p o n e nt 2 t h at c o nt ai ns i nf or m ati o n of s a c c h ari n v ari ati o n a n d pri n ci p al 
c o m p o n e nt 1 c o nt ai ns i nf or m ati o n o n t h e a v er a g e tr e n d of all s a m pl es. It c a n b e s e e n t h at t h er e ar e 
cl e ar i n di c ati o ns of t h e c h a n g e i n s a c c h ari n l e v els visi bl e i n t h e s c or es pl ot t h at w er e f ar m or e diffi c ult 
t o s e e i n t h e r a w a n d pr e-tr e at e d s p e ctr al pl ots. 
 
A g ai n, t h e s a m e d e gr e e of dis cri mi n ati o n of s a c c h ari n l e v el is e vi d e nt i n r u n 2. T h es e r es ult s l o o k 
pr o misi n g, wit h t h e diff er e nt s o di u m s a c c h ari n l e v els b ei n g e asil y d efi n a bl e a n d q uit e st e a d y b ut t h e 
s pi k es w hi c h a p p e ar i n e a c h c ell ar e of c o n c er n. T h o u g h w h e n l o o k e d at cl os el y t h es e ar e o nl y o n e or 
t w o d at a p oi nt s ass o ci at e d wit h t h e st art a n d e n d of e a c h c ell b ef or e t h e NI R pr o b e st o ps r e c or di n g. 
Cl e arl y t h es e p oi nt s n e e d r e m o vi n g fr o m t h e l o g g e d d at a i n t h e pr e- pr o c essi n g st e ps.  
 
 
4. 2 C ali b r ati o n M o d elli n g u si n g O n-li n e NI R M e as u r e m e nts 
 
4. 2. 1 Off li n e A n al ysis 
 
I n b uil di n g a c ali br ati o n m o d el it is n e c ess ar y t o d et er mi n e a n off-li n e a n al ysis m et h o d, i. e. r ef er e n c e 
m et h o d t o q u a ntif y t a bl et c o m p ositi o n. T his m e as ur e is t h e n us e d wit h t h e pr e- pr o c ess e d s p e ctr os c o pi c 
d at a t o d e v el o p a p arti al l e ast s q u ar es b as e d c ali br ati o n m o d el. T h e q u alit y m e as ur e m e nt of i nt er est 
w as p er c e nt a g e of s a c c h ari n pr es e nt i n t h e gr a n ul e s a m pl es t a k e n d uri n g pr o c ess o p er ati o n. A n off-
li n e U V s p e ctr o m etr y m et h o d w as d e v el o p e d t h at i n v ol v e d t h e li q ui d dil uti o n of t h e gr a n ul e s a m pl e s 
t o a n a bs or b a n c e b et w e e n z er o a n d o n e s o t h at t h e B e er- L a m b ert l a w c o ul d b e a p pli e d, t h e filtr ati o n of 
t h e n o n-s ol u bl e c o m p o n e nt of t h e pl a c e b o a n d t h e n fi n all y t h e m e as ur e m e nt of t h e s a m pl e. Aft er 
a n al ysi n g t h e s o di u m s a c c h ari n/ pl a c e b o mi x wit h t h e U V s p e ctr o m et er it w as f o u n d t h at t h er e w as a n 
a bs or b a n c e p e a k at 2 6 9 n m t h at w as o nl y aff e ct e d b y t h e s a c c h ari n. It w as t h e a bs or b a n c e at t hi s p e a k 
fr o m w hi c h t h e c ali br ati o n li n e w as d e v el o p e d a n d w hi c h r e ali s e d t h e f urt h er q u a ntifi c ati o n of t h e 
a m o u nt of s o di u m s a c c h ari n pr es e nt. T h e c ali br ati o n li n e ( R »2 1) is gi v e n i n Fi g ur e 7.  
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Figure 7: Sodium Saccharin UV Spectrometer Calibration Line, y = 7.177x – 0.0039; R2=1 
 
 
 
Figure 8 – Saccharin Concentration from run 1 
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 Fi g ur e 9 – S a c c h ari n C o n c e ntr ati o n fr o m r u n 2  
 
F i g ur e 8 a n d 9 s h o w t h e r es ult s fr o m t h e offli n e a n al ysis f or all t h e c ell s a n al y z e d. F or e a c h c ell, t hr e e 
s am pl es w er e t a k e n a n d f or e a c h s a m pl e t h e U V m e as ur e m e nt w as r e p e at e d t hr e e ti m es t h us e a c h p oi nt 
i n Fi g ur es 8 a n d 9 is a n a v er a g e of ni n e v al u es. As c a n b e o bs er v e d t h e v ari a bilit y fr o m c ell t o c ell f or 
p a rti c ul ar s a c c h ari n c o n c e ntr ati o n s ar e r el ati v el y l o w, b ut t h er e is sli g htl y m or e s a c c h ari n pr es e nt t h a n 
w o ul d h a v e b e e n e x p e ct e d. It is li k el y t h at at t h e hi g h er s a c c h ari n c o n c e ntr ati o ns t h er e will b e a l ar g er 
e rr or d u e t o t h e dil uti o ns t h at w er e n e e d e d. F or t h e 2 0 % a n d 3 0 % s a c c h ari n a f urt h er dil uti o n w as 
r e q uir e d t o k e e p t h e a bs or pti o n b el o w a v al u e of o n e w hi c h will i n cr e as e t h e err or. As a c o ns e q u e n c e 
of d oi n g t h e e xtr a dil uti o n, t h e s a c c h ari n c o n c e ntr ati o n o bt ai n e d n e e ds t o b e m ulti pli e d b y a dil uti o n 
f a ct or i n or d er t o g et t h e tr u e s a c c h ari n c o n c e ntr ati o n; t his will m a g nif y a n y err ors pr es e nt. 
 
4. 2. 2 NI R C ali b r ati o n M o d elli n g 
A n NI R c ali br ati o n m o d el b as e d o n t h e d at a g e n er at e d fr o m t h e offli n e a n al ysis w as c o nstr u ct e d. T h e 
off li n e a n al ysis pr o d u c e d t h e a v er a g e bl e n d u nif or mit y f or t h e s a m pl e t a k e n fr o m t h e c ell. It is ass u m e d 
t h at t h e s a m pl e is r e pr es e nt ati v e of t h e w h ol e c ell. T h e s p e ctr a r e c or d e d wit hi n e a c h c ell w er e a v er a g e d 
t o pr o d u c e o n e s p e ctr u m f or e a c h c ell. T h e d at a s et w as s plit i nt o a c ali br ati o n s et a n d a v ali d ati o n s et. 
T h e  c ali br ati o n s et c o nt ai n e d all t h e s a m pl es fr o m R u n 2 e x cl u di n g c ell s F 8 C 4 a n d F 1 0 C 4 (s o t h at t h e y 
c o ul d b e i n cl u d e d i n t h e v ali d ati o n d at as et). T h e r est of t h e s a m pl es w er e us e d as a v ali d ati o n s et, 
w hi c h c o nsist e d of all t h e s a m pl es fr o m R u n 1 a n d c ell s F 8 C 4 a n d F 1 0 C 4. T h e c ali br ati o n m o d el w as 
t h e n b uilt usi n g P L S b as e d o n t h e a v er a g e bl e n d u nif or mit y a n d t h e s p e ctr a. Fi v e l at e nt v ari a bl es w er e 
r et ai n e d e x pl ai ni n g i n e x c ess of 9 9 % v ari ati o n. Fi n all y, t h e m e as ur e us e d t o ass ess t h e m o d el fit w as 
t h e R o ot M e a n S q u ar e Err or of Pr e di cti o n R M S E P : 
 
R M S E P =
x i - xˆ i( ) 2
i= 1
Nå
N            
( 2) 
 
w h er e x i xˆ i r e pr es e nts a s p e cifi c m e as ur e m e nt,  t h e pr e di cti o n f or t h at s a m pl e a n d N  is t h e n u m b er of 
s a m pl es. T h e P L S m o d el w as t h e n b uilt a n d t h e r es ult s ar e s h o w n i n Fi g ur es 1 0 a n d 1 1. Fi g ur e 1 0 
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shows the ability of the model to be able to predict both the calibration and the validation dataset using 
the calibration model. It can be seen that distinct clusters occur for each concentration.  
 
The differences in RMSE can be seen from applying different pre-processing techniques in different 
combinations in Table 5 and it can be seen that SNV and Savitzky-Golay first derivative gave the 
lowest validation errors. 
 
Table 5: The effect of different pre-processing techniques on model accuracy  
Pre-Processing Calibration + Validation 
Sample RMSE (%) 
Validation Samples 
REMSEP (%) 
SNV 0.618 0.857 
SNV + Savitzky-Golay 1st Derivative 0.412 0.483 
SNV + Savitzky-Golay 2nd Derivative 0.410 0.548 
Savitzky-Golay 1st Derivative 0.884 1.26 
Savitzky-Golay 2nd Derivative 0.952 1.37 
Multiplicative Scatter Correction 1.29 1.83 
 
Using this data the final model was build using SNV and a Saviztky-Golay first derivative. The results 
of this are shown in Figures 10 and 11. 
 
 
Figure 10: Actual concentration vs. predicted concentration for the calibration and validation data 
sets. RMSE = 0.412% 
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Figure 11:  Actual concentration vs. predicted concentration for validation data. RMSEP = 0.483% 
 
Figure 11 shows the ability of the model to predict the concentration of cells with known saccharin 
content. The prediction error is slightly higher when looking just at validation data as would be 
expected. The lower concentrations are predicted with smaller errors as can be observed from the fact 
that the clusters are tight and lie on the ideal line. This is confirmed from the RMSEP for the saccharin 
concentration (Table 6). 
 
 
Table 6: Calculated RMSEP for each saccharin concentration 
Target Saccharin Concentration RMSE (%) 
5 % 0.165 
7.5% 0.139 
10 % 0.170 
20 % 0.500 
30 % 0.641 
 
 
4.3 Online Blend Uniformity Monitoring Using the Calibration Model  
The PLS model was then used to show the monitoring ability of the probe on the saccharin 
concentration within the same run. It is important to highlight the difference, where before the PLS 
model was being used to predict the average saccharin concentration over a cell, the model is now 
being used to predict the saccharin concentration from each NIR reading taken. It is difficult to quantify 
how accurate this is as there is no offline data to cross validate this with. However, it is important to 
note that both Figure 12 and Figure 13 both follow the same trends found in the offline measurements 
that can be seen in Figures 8 and 9. This is particularly important for Run 1 as this is validation data 
that was not used to build the PLS model. 
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Figure 12. Prediction for all NIR readings during Run 1 
 
 
Figure 13. Prediction for all NIR readings during Run 2 
 
By calculating the sample mass the NIR probe has measured in one dryer cell, it is also possible to 
look at the blend uniformity measured online at a unit dose scale. The total measured sample mass 
over one cell can be seen in Table7: 
Table 7: Granule Properties 
Granule Bulk Density (g/cm3) No. of NIR Samples 
Taken 
Measured Mass (mg) 
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Placebo Granule 10% 
Saccharin 
0.599 32 153.2 
 
Figure 14-15 show the monitoring of both the assay and the uniformity of the saccharin concentration 
within each cell at a sub unit dose scale of scrutiny. The assay stays within the potency limits in both 
runs, the only cells which breach the +/-10% limits are those which involve a transition in 
concentration, where the exact concentration of saccharin is not known.  
The uniformity stays within limits for the entirety of run 1, however run 2 has a couple of cells where 
the uniformity isn’t with specification. The first 10% concentration period in run 2 has a couple of 
disturbances which can be seen in Figure 13 where the measured concentration is higher than expected 
and it is these disturbances which push the RSD up. The lowest concentration set point at 5% saccharin 
also has a relatively high RSD, which was due to the feeder struggling to maintain its set point at such 
low concentrations. This could be rectified by using a feeder with a more suitable set up when dosing 
very small mass flow rates. 
 
Figure 14: Online monitoring using NIR analysis of Sodium Saccharin showing Assay and RSD on 
Run 1. Boundary conditions are positioned at +/- 10% of the target set point for the Assay and 5% 
limit for the RSD. 
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Figure 15: Online monitoring using NIR analysis of Sodium Saccharin showing Assay and RSD on 
Run 2. Boundary conditions are positioned at +/- 10% of the target set point for the Assay and 5% 
limit for the RSD. 
There are advantages to measuring the blend uniformity at both unit dose scale, and at the sample size 
scale. The unit dose scale gives a better indication of the blend uniformity that will be seen in the final 
tablets. At the sample size scale however it could be possible to see if there will be poor intra-tablet 
uniformity. 
It is possible to compare different sample sizes and the effect that this has on the RSD. It is worth 
noting that as long as all the data is used; changing the scale of scrutiny will not change the final assay, 
only the RSD.  
The effect of changing the scale of scrutiny can be seen in Figure 16 and 17, where 1, 10, 20 and 30 
samples from each condition are used to calculate the blend uniformity over each concentration. 
Table 8: Calculated Sample Size for Varying Number of Samples in Averaging 
No Samples Calculated Sample Size (mg) 
1 15.7 
10 50.7 
20 89.7 
30 128.7 
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 Figure 16: Effect of increasing the number of measurements per average to move from single 
measurements towards a unit dose scale of scrutiny for Run 1 
 
Figure 17: Effect of increasing the number of measurements per average to move from single 
measurements towards a unit dose scale of scrutiny for Run 2 
 
As the number of samples used is increased in order to move towards a unit dose scale of scrutiny, it 
would be expected that the RSD would decrease. However, the RSD will only decrease towards the 
population RSD. Figure 16 and Figure 17 show that it is important to measure based on unit dose scale 
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of scrutiny in order to quantify the real variability and not a variability amplified by spectral noise and 
intra tablet variability.  
5. Conclusions 
Process Analytical Technologies are potentially a valuable tool for improving the monitoring and 
control of processes. They offer a move from a control strategy that is predominantly based on off-line 
laboratory analysis, to one where on-line measurement can rapidly indicate deviations and allow 
appropriate action to be taken. Unfortunately, the complexity of the physical system makes calibration 
model construction problematic and traditional methods are compromised unless care is taken in probe 
implementation and data preprocessing. 
 
This paper has demonstrated that it is possible to monitor blend uniformity of a continuous tableting 
line using online NIR spectroscopy. It has been shown that through the use of PLS regression it is 
possible to detect deviations in the blend uniformity. This paper also highlights the need to analyze the 
data generated by the NIR probe at the correct scale of scrutiny. If the wrong scale of scrutiny is used, 
then the variability may be amplified or filtered leading to incorrect judgements of the product quality. 
In arriving at the results described this is not the only issue that arises in application. The quality of 
the results is significantly impacted by the mathematical signal pre-processing approaches chosen to 
move from raw data to prediction. An ‘optimal’ set of methods is not easily identifiable and requires 
significant data and knowledge of the approach to configure the processing steps. Importantly, what is 
‘optimal pre-processing’ for one application is not necessarily so for another. One of the greatest 
challenges we faced in moving from first implementation of the probe to a working system was that 
decisions such as pre-processing proceed in parallel with probe commissioning, data gathering and 
experimental design thus in moving towards ‘optimal’ probe functionality it can be difficult to identify 
where attention needs to be focused. Such considerations are discussed further in a comprehensive 
technology review bringing together the experiences of multiple teams [29]. 
 
Looking beyond the scope of this paper, a relatively straightforward early warning scheme for 
deviations can subsequently be implemented through applying statistical process control the form of 
which is discussed by Silva et al [30]. It is also demonstrated that if the need is to implement a control 
system to compensate for disturbances, a quantitative calibration model can be constructed for closed 
loop control or use in a feedforward scheme. 
 
The availability of more frequent measurements of critical quality attributes has the potential to make 
a paradigm shift in the control philosophy employed. A move towards a more responsive control policy 
than that accepted by regulatory authorities in the past offers the opportunity for greater product 
consistency and increased productivity through greater insight into deviations. This is particularly 
crucial in the case of a continuous processing line where the batch-wise demonstration of consistency 
is no longer applicable and the measurement of instantaneous composition is required. 
 
While this paper has concentrated on on-line implementation of NIR measurements as part of a control 
strategy, the benefits of PAT may arise without full implementation. The understanding gained by on-
line implementation in the design stage may result knowledge that allows an effective control system 
to be designed that does not require permanent on-line NIR implementation.   
 
 
Acknowledgements 
The authors would like to acknowledge the financial support of the UK Engineering and Physical 
Sciences Research Council grant EP/G037620/1, the UK Technology Strategy Board and the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
significant contribution of GSK and GEA Pharma Systems to all aspects of the technical work 
described. 
 
References 
 
[1] Colón Y.M., Vargas J., Sánchez E., Navarro G., Romañach R.J. (2017). ‘Assessment of 
Robustness for a Near-Infrared Concentration Model for Real-Time Release Testing in a 
Continuous Manufacturing Process’, Journal of Pharmaceutical Innovation, Volume 12, Issue 
1, pp 14–25 
[2] Lee S.L., O’Connor T.F., Yang X., Cruz C.N., Chatterjee S., Madurawe R.D., Moore 
C.M.V., Yu L.X., Woodcock J. (2015), ‘Modernizing Pharmaceutical Manufacturing: from 
Batch to Continuous Production’, Journal of Pharmaceutical Innovation, Volume 10, Issue 3, 
pp 191–199 
[3] Yu L.X., Kopcha M. (2017). ‘The future of pharmaceutical quality and the path to get there’, 
International Journal of Pharmaceutics, 528 (2017) 354–359 
[4] Holý R, Pozivil J (2002). Batch control system project for a pharmaceutical plant. ISA 
Transactions  41(2):245-254. 
[5] Buchholz S. (2010). ‘Future manufacturing approaches in the chemical and pharmaceutical 
industry’, Chemical Engineering and Processing 49 (2010) 993–995  
[6] Leuenberger H (2001). ‘New trends in the production of pharmaceutical granules: batch 
versus continuous processing’. European Journal of Pharmaceutics and Biopharmaceutics  
52(3):289-296. 
[7] Vervaet C., Remon J.P. (2005). ‘Continuous granulation in the pharmaceutical industry’. 
Chemical Engineering Science  60(14):3949-3957. 
[8] Plumb K. (2005). ‘Continuous Processing in the Pharmaceutical Industry: Changing the Mind 
Set.’, Chemical Engineering Research and Design  83(6):730-738. 
[9] Fonteyne M., Vercruysse J., De Leersnyder F., Van Snick B., Vervaet C., Remnon J.P.,  De 
Beer T. (2015). Process analytical technology for continuous manufacturing of solid dosage 
forms. Trends in Analytical Chemistry, Vol 67, pp 159-166. 
[10] Hattori Y., Otsuka M. (2017). ‘Modeling of feed-forward control using the partial least 
squares regression method in the tablet compression process’. International Journal of 
Pharmaceutics, 524, 407-413 
[11] De Beer T., Fonteyne M., Saerens L., Remon J.P., Vervaet C. (2011). ‘Near infrared and 
Raman spectroscopy for the in-process monitoring of pharmaceutical processes’. 
International Journal of Pharmaceutics  417:32-47. 
[12] Menezes J.C., Ferreira A.P., Rodrigues L.O., Brás L.P., Alves T.P. (2009). ‘Chemometrics 
Role within the PAT Context: Examples from Primary Pharmaceutical Manufacturing’.  
Comprehensive Chemometrics, ed., Oxford: Elsevier. p 313-355. 
[13] Roggo Y., Chalus P., Maurer L., Lema-Martinez C., Edmond A., Jent N. (2007). ‘A review 
of near infrared spectroscopy and chemometrics in pharmaceutical technologies’. Journal of 
Pharmaceutical and Biomedical Analysis  44(3):683-700. 
[14] Vanarase A.U., Alacla M., Jerez Rozo J.I., Muzzio F. J., Romanach R.J. (2010). ‘Real-time 
monitoring of drug concentration in a continuous powder mixing process using NIR 
spectroscopy’. Chemical Engineering Science 65:5728-5733. 
[15] Koller D.M., Posch A., Horl G., Voura C., Radl S., Urbanetz N., Fraser S.D., Tritthart W, 
Reiter F, Schlingmann M., Khinast J.G. (2011). ‘Continuous quantitative monitoring of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
powder mixing dynamics by near-infrared spectroscopy’. Powder Technology, 205(2011):87-
96. 
[16] Shi Z., Cogdill R.P., Short S.M., Anderson C.A. (2008). ‘Process Characterization of powder 
blending by near-infrared spectroscopy: Blend end-points and beyond’. Journal of 
Parmaceutical and Biomedical Analysis  47(2008):738-745. 
[17] Pawar P., Wang Y., Keyvan G., Callegari G., Cuitino A., Muzzio F. (2016) ‘Enabling real 
time release testing by NIR prediction of dissolution of tablets made by continuous direct 
compression (CDC)’, International Journal of Pharmaceutics, Volume 512, pp 96-107 
[18] Järvinen K, Hoehe W, Järvinen M, Poutiainen S, Juuti M, Borchert S. (2013). ‘In-line 
monitoring of the drug content of powder mixtures and tablets by near-infrared spectroscopy 
during the continuous direct compression tableting process.’. Eur J Pharm Sci., Vol 48, pp 
680-688 
[19] Vargas J.M., Nielsen S., Cárdenas V., Gonzalez A., Aymat E.Y., Almodovar E., Classe G., 
Colón Y., Sanchez E., Romañach R.J. (2018). ‘Process analytical technology in continuous 
manufacturing of a commercial pharmaceutical product’, International Journal of 
Pharmaceutics, 538 (2018) 167–178 
[20] Wahl P.R., Fruhmann G., Sacher S., Straka G., Sowinski S., Khinast J.G. (2014). ‘PAT for 
tableting: inline monitoring of API and excipients via NIR spectroscopy.’ Eur J Pharm 
Biopharm. Vol 87, pp 271-8.  
[21] Casian T., Reznek A., Vonica-Gligor A.L., Renterghem J., De Beer T., Tomuță I. (2017). 
‘Development, validation and comparison of near infrared and Raman spectroscopic methods 
for fast characterization of tablets with amlodipine and valsartan’, Talanta, Volume 167, 15 
May 2017, Pages 333-343  
[22] Li Y., Anderson C.A., Drennen III, J.K., Airiau C., Igne B. (2018). ‘Method Development 
and Validation of an Inline Process Analytical Technology Method for Blend Monitoring in 
the Tablet Feed Frame Using Raman Spectroscopy’, Analytical Chemistry, 90 (14), 8436-
8444 
[23] Chen Z, Morris A.J. (2011). ‘Process analytical technologies and real time process control a 
review of some spectroscopic issues and challenges’. Journal of Process Control 21:1467-
1482. 
[24] Blanco M., Peguero A. (2010). ‘Influence of physical factors on the accuracy of calibration 
models for NIR spectroscopy’. Journal of Pharmaceutical and Biomedical Analysis  
52(2010):59-65. 
[25] Banfai B., Ganzier K., Kemeny S. (2007). ‘Content uniformity and assay requirements in 
current regulations’. Journal of Chromatography 1156:206-212. 
[26] Kleinebudde P., Khinast J., Rantanen J. (2017). ‘Continuous Manufacturing of 
Pharmaceuticals.’,  Wiley, ISBN: 978-1-119-00132-4 
[27] Triadaphillou S., Martin E.B., Montague G.A., Norden A., Jeffkins P., Stimpson S. (2007). 
‘Fermentation process tracking through enhanced spectral calibration modeling’. 
Biotechnology and Bioengineering, 97 (3), 554-567. 
[28] Gerretzen J. Szy���a E., Jansen J.J., Bart J., van Manen H.J., van den Heuvel E.R, 
Buydens L.M.C. (2015). ‘Simple and Effective Way for Data Preprocessing Selection Based 
on Design of Experiments’, Anal. Chem. 2015, 87, 12096−12103  
[29] Laske S., Paudel A., Scheibelhofer O., Sacher S., Hörmann T., & Khinast J. (2017). ‘A 
review of PAT strategies in secondary solid oral dosage manufacturing of small 
molecules’. Journal of Pharmaceutical Sciences Vol 106, Issue 3, March, pp 667-712 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
[30] Silva A.F., Sarraguça M.C., Fonteyne M., Vercruysse J., De Leersnyder F., Vanhoorne V., 
Bostijn N., Verstraeten M., Vervaet C., Remon J.P., De Beer T., Lopes J.A. (2017). 
‘Multivariate statistical process control of a continuous pharmaceutical twin-screw 
granulation and fluid bed drying process’, International Journal of Pharmaceutics, 528 (2017) 
242–252 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
